Shaily engineering plastics reports strong FY25 results, driven by healthcare segment

Shaily Engineering Plastics Limited held its 45th Annual General Meeting on September 27, 2025, revealing a robust financial year 2024-25. The company achieved a 22% revenue growth, reaching Rs. 787 crores. EBITDA increased by 45% year-on-year to Rs. 178 crores, with margins expanding by 350 basis points to 22.7%. Net profit after tax (PAT) saw a 63% increase, reaching approximately Rs. 93 crores. This strong performance was primarily driven by a 53% surge in the healthcare segment, which currently accounts for 21% of the overall revenue mix, projected to grow to 30-35% within the next two years.

Key developments included signing eight new contracts with global pharma players for GLP-1, insulin, parathyroid hormone, and migraine therapies. To support growing demand, Shaily is investing approximately Rs. 150 Cr to expand pen manufacturing capacity by an additional 40-50 million units, aiming for completion by December 2026. The company also expanded its global reach by establishing Shaily Innovations FZCO subsidiary in Dubai in January 2025.

The consumer segment reported Rs. 561 crores in revenue, a 17% year-on-year growth, forming 71% of the overall revenue. The industrial segment grew by 12% to Rs. 61 crores, comprising 8% of the total revenue. Overall capacity utilization stood at approximately 50%, with plans to reach 80% by the end of FY27. Debt was approximately Rs. 218 crores, with ROCE at 24.4% and ROE at 18.5%.